Compare UP & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | CLLS |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | France |
| Employees | 1866 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.3M | 384.3M |
| IPO Year | N/A | 2014 |
| Metric | UP | CLLS |
|---|---|---|
| Price | $0.52 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.8M | 48.3K |
| Earning Date | 04-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.10 |
| 52 Week High | $3.50 | $5.48 |
| Indicator | UP | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 42.08 |
| Support Level | $0.49 | $3.32 |
| Resistance Level | $0.59 | $3.83 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 29.21 | 22.37 |
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.